MaxCyte,
Inc.
("MaxCyte" or the "Company")
Grant of Options, RSUs and
PSUs and PDMR Dealing
Rockville, Maryland - 20 March
2024: MaxCyte Inc., (NASDAQ:
MXCT; LSE: MXCT), a leading, cell-engineering focused company
providing enabling platform technologies to advance the discovery,
development, and commercialization of next-generation cell
therapeutics and innovative bioprocessing applications, announces
that on 15 March 2024, a target grant of 400,000 performance stock units
("PSUs") were granted to Maher Masoud, President, Chief Executive
Officer and Director of the Company, and 225,000 options in respect
of common stock in the Company, 81,250 restricted stock units
("RSUs") and a target grant of 31,250 PSUs were granted to Douglas
Swirsky, Chief Financial Officer of the Company.
Details of the stock options
The options granted to Mr. Swirsky
vest as to 25% of the total grant on the first anniversary of the
date of grant, and the remaining 75% vest in 36 equal monthly
instalments thereafter.
The options granted to Mr. Swirsky
have an exercise period of 10 years from date of grant, at which
time they will expire, and have an exercise price of $4.31, being
equal to the closing price of MaxCyte's common stock on Nasdaq on
15 March 2024.
Details of the RSUs
Each RSU represents the contingent
right to receive one share of common stock in the Company. The RSUs
granted to Mr. Swirsky vest as to 25% on each of the first, second,
third and fourth anniversary of the date of grant. No exercise
price is payable on vesting or settlement of the RSUs.
Details of the PSUs
Each PSU represents the contingent
right to receive one share of common stock in the Company upon the
achievement of specified performance metrics. The PSU grants made
to Messrs. Masoud and Swirsky on 15 March 2024 represent a number
of shares of common stock to be earned if the target level of
performance is achieved. The performance period continues through
31 December 2026, after which time the level of performance
achievement will be determined by the Board of Directors or an
authorized committee thereof. The actual number of shares of
common stock underlying the PSUs to be earned will be between 0%
and 125% of the target number of PSUs, depending on the level of
achievement of such performance metrics. No exercise price is
payable on the vesting or settlement of the PSUs.
The information in the tables below
is provided in accordance with the requirements of the UK Market
Abuse Regulation.
About MaxCyte
At MaxCyte, we pursue cell
engineering excellence to maximize the potential of cells to
improve patients' lives. We have spent more than 20 years honing
our expertise by building best-in-class platforms, perfecting the
art of the transfection workflow, and venturing beyond today's
processes to innovate tomorrow's solutions. Our ExPERT™ platform,
which is based on our Flow Electroporation® technology, has been
designed to support the rapidly expanding cell therapy market and
can be utilized across the continuum of the high-growth cell
therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The
ExPERT family of products includes: four instruments, the ATx™,
STx™, GTx™ and VLx™; a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio.
By providing our partners
with the right technology platform, as well as scientific,
technical, and regulatory support, we aim to guide them on their
journey to transform human health. Learn more
at maxcyte.com and follow us on
Twitter and
LinkedIn.
MaxCyte Contacts:
|
US IR
Adviser
Gilmartin
Group
David
Deuchler, CFA
|
+1 415-937-5400
ir@maxcyte.com
|
|
Nominated Adviser and Joint
Corporate Broker
Panmure
Gordon
Emma Earl /
Freddy Crossley
Corporate
Broking
Rupert
Dearden
|
+44 (0)20 7886 2500
|
|
UK IR
Adviser
ICR
Consilium
Mary-Jane
Elliott
Chris
Welsh
|
+44 (0)203 709 5700
maxcyte@consilium-comms.com
|
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Maher Masoud
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
President, CEO and
Director
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
MaxCyte Inc.
|
|
b)
|
LEI
|
54930053YHXULRFCU991
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Common stock of $0.01
each
|
|
|
|
|
Identification code
|
US57777K1060
|
|
|
|
|
b)
|
Nature of the transaction
|
Grant of PSUs in respect of common stock
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Exercise Price(s)
|
Volume(s)
|
|
|
|
|
N/A
|
400,000 PSUs
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
400,000 PSUs (up to 500,000 shares
of common stock if performance metrics are fully
satisfied)
|
|
- Price
|
N/A
|
|
e)
|
Date of the transaction
|
15 March,
2024
|
|
f)
|
Place of the transaction
|
US Stock Exchange, Nasdaq
|
|
1
|
Details of the person
discharging managerial responsibilities / person closely
associated
|
|
a)
|
Name
|
Douglas
Swirsky
|
|
2
|
Reason for the
notification
|
|
a)
|
Position/status
|
Chief
Financial Officer
|
|
b)
|
Initial
notification /Amendment
|
Initial
notification
|
|
3
|
Details of the issuer,
emission allowance market participant, auction platform, auctioneer
or auction monitor
|
|
a)
|
Name
|
MaxCyte
Inc.
|
|
b)
|
LEI
|
54930053YHXULRFCU991
|
|
4
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description
of the financial instrument, type of instrument
|
Common
stock of $0.01 each
|
|
|
|
|
Identification code
|
US57777K1060
|
|
|
|
|
b)
|
Nature of
the transaction
|
Grant
of options, RSUs and PSUs in respect of
common stock
|
|
c)
|
Price(s)
and volume(s)
|
|
Options:
|
|
|
|
|
|
Exercise
Price(s)
|
Volume(s)
|
|
|
|
|
$4.31
|
225,000
|
|
|
|
RSUs:
|
|
|
Exercise
Price(s)
|
Volume(s)
|
|
|
|
N/A
|
81,250
|
|
|
|
PSUs:
|
|
|
|
Exercise
Price(s)
|
Volume(s)
|
|
|
N/A
|
31,250
|
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
|
|
|
-
Aggregated volume
|
225,000
options, 81,250 RSUs and 31,250 PSUs (up to 345,313 shares of
common stock if performance metrics for the PSUs are fully
satisfied)
|
|
|
|
|
-
Price
|
$4.31 for
the options; no exercise price for the RSUs and PSUs
|
|
|
|
|
e)
|
Date of the
transaction
|
15
March, 2024
|
|
f)
|
Place of
the transaction
|
US Stock
Exchange, Nasdaq
|